CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Monoclonal antibody targeting aurora-a kinase

Référence

84999-01

Statut des brevets

French patent application FR0207212 filed on June 12nd, 2002 and entitled “New monoclonal antibody specific for aurora-a kinase, useful for diagnosis, prognosis and treatment of solid tumors, also for drug screening”

Inventeurs

Claude PRIGENT
Anne MARTIN

Statut commercial

Exclusive and non exclusive licences

Laboratoire

Institut de Génétique et de Développement de Rennes (IGDR), UMR 6061, in Rennes, France, http://www.umr6061.univ-rennes1.fr/

Description

CONTEXT

The objective of this invention is to provide a reliable anti-aurora A monoclonal antibody, which links with this oncogene protein with a sufficient specificity and sensitivity, in order to envisage its use for experimental research, as well as in fields of diagnosis, prognosis and treatment of cancers. 

TECHNICAL DESCRIPTION

The present invention concerns monoclonal antibody which targets the mammal aurora-A kinase (human and mouse). As the overexpression of aurora-A kinase has been observed in many tumors, it is very important to assess its expression.
Mice were injected with human recombinant aurora-A kinase and then sacrificed. Spleen cells were extracted and fused with immortalized hamster cells to obtain hybridoma. After many screening stages, an hybridoma was isolated to produce an antibody with a high affinity for the aurora-A kinase. 

BENEFITS

Advantageously, in the context of the invention, the determination of a quantity of aurora-A protein lower than or greater than a physiological threshold determined as a function of the biological sample, shows respectively a good or a poor prognosis for the diagnosed cancer. 

INDUSTRIAL APPLICATIONS

This innovation can be used as a research reagent in cancer research; as an in vitro diagnostic or prognostic method for cancers; or as a method for screening inhibitors of aurora-A kinase.

For further information, please contact us (Ref 84999-01)

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents